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COMMENTARY
Positive direct antiglobulin test 
in post-artesunate delayed haemolysis: more 
than a coincidence?
Daniel Camprubí1* , Arturo Pereira2, Natalia Rodriguez‑Valero1, Alex Almuedo1,3, Rosauro Varo1, 
Climent Casals‑Pascual4, Quique Bassat1,5,6,7, Denis Malvy8 and Jose Muñoz1
Abstract 
Background: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Removing once‑
infected “pitted” erythrocytes by the spleen is the most accepted mechanism of haemolysis in these cases. However, 
an increasing number of cases with positive direct antiglobulin test (DAT) haemolysis after AS have been reported.
Methods: All malaria cases seen at Hospital Clinic of Barcelona between 2015 and 2017 were retrospectively 
reviewed. Clinical, parasitological and laboratory data from patients treated with intravenous artesunate—specifically 
looking for delayed haemolysis and DAT—was collected.
Results: Among the 36 severe malaria patients treated with artesunate at the hospital, 10 (27.8%) developed post‑
artesunate delayed haemolysis. Out of these, DAT was performed in six, being positive in four of them (at least 40%). 
DAT was positive only for complement—without IgG—suggesting drug‑dependent immune‑haemolytic anaemia of 
the immune‑complex type. Three of the four patients were treated with corticosteroids and two also received blood 
transfusion, with a complete recovery.
Conclusions: Drug‑induced auto‑immune phenomena in post‑artesunate delayed haemolysis may be underre‑
ported and must be considered. The role of corticosteroids should be reassessed.
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Background
Intravenous artesunate (AS) has been established as the 
first-line treatment for Plasmodium falciparum severe 
malaria after demonstrating its superiority over qui-
nine, in terms of reduction of mortality and neurological 
sequelae, in multicentre randomized clinical trials, with 
no serious drug-related adverse events initially reported 
[1–3]. However, as a consequence of the generalized use 
of AS, the post-artesunate delayed haemolytic anaemia is 
increasingly been recognized and reported, even follow-
ing the administration of oral artemisinin-based combi-
nation therapy (ACT) [3, 4].
In spite of conflicting case-definitions [5, 6], post-
artesunate delayed haemolysis (PADH) pattern has gen-
erally been defined as the presence of haemolysis with 
a > 10% decrease in haemoglobin level or a > 10% rise in 
LDH concentrations occurring more than 8  days after 
initiation of treatment [5]. PADH is estimated to occur 
in about 15–30% of malarial patients treated with AS, 
mainly affecting non-immune patients (presumably 
patients with no immunity to malaria) [7–9]. Although 
the pathophysiology of PADH remains unclear, splenic 
“pitting” of once-infected erythrocytes has been postu-
lated as the most plausible mechanism of haemolysis [5–
9]. Unlike other anti-malarial agents, artemisinins turn 
intraerythrocytic trophozoites into non-viable pyknotic 
forms which are removed by the spleen. It is supposed 
that the decreased lifespan of the resulting once-infected 
erythrocytes would lead to haemolytic events between 
Open Access
Malaria Journal
*Correspondence:  dcamprub@clinic.cat 
1 ISGlobal, Hospital Clínic ‑ Universitat de Barcelona, Barcelona, Spain
Full list of author information is available at the end of the article
Page 2 of 7Camprubí et al. Malar J          (2019) 18:123 
7 and 28  days after anti-malarial treatment was started 
[5–9]. Remarkably, although only a handful of cases with 
positive direct antiglobulin test (DAT) after AS has been 
described, they are increasingly being reported [10–16]. 
This fact raises the possibility of drug-induced auto-
immune mechanisms contributing to PADH in some 
patients.
The objective of this report was to review the clinical 
and immunohaematological characteristics of patients 
with positive DAT in the context of PADH.
Methods
All the 83 consecutive patients diagnosed with malaria 
attended at Hospital Clínic of Barcelona, Spain, between 
January 2015 and December 2017, were retrospectively 
reviewed. Thirty-nine per cent of them were migrants 
or visiting friends and relatives (VFR) and the remaining 
61% were tourists or business travellers. Of these, specific 
clinical, parasitological and laboratory data was collected 
from the 36 patients diagnosed with severe malaria 
and treated with AS. Severe malaria was defined based 
on World Health Organization (WHO) malaria sever-
ity criteria [17]. PADH was defined as > 10% decrease in 
haemoglobin levels or > 10% rise in LDH concentrations 
occurring between the 8th and the 28th day after the first 
dose of AS, in patients with evidence of other parameters 
of haemolysis, such as hyperbilirubinaemia or decrease of 
haptoglobin in plasma. Hyperbilirubinaemia was defined 
as any increase above the normal limits with a previous 
normal determination or an increase > 10% if the previ-
ous determination was high. Decrease in plasma hapto-
globin was defined as any decrease below normal limits 
with a previous normal determination.
The direct antiglobulin test (DAT), also known as direct 
Coombs test, was performed by the tube method with 
polyspecific antiglobulin (Anti-Human Globulin Mono-
Type, Grifols Diagnostics AG, Düdingen, Switzerland) 
and monospecific anti-IgG and anti-C3d/C3c (both from 
Sanquin, Amsterdam, The Netherlands).
Results
PADH was diagnosed in 10 of the 36 (27.8%) malaria 
patients treated with intravenous AS. Median age of the 
affected patients was 45 years (interquartile range (IQR): 
33.25–54.25  years) with 80% being males. All patients 
lived in non-endemic areas and acquired the infection 
through travelling to malaria-endemic areas. No patients 
were considered semi-immune by the study investigators 
[18].
DAT was positive for complement and negative for IgG 
in four of the six Plasmodium falciparum malaria cases 
in which it was performed (see below), which represents 
at least 40% (4/10) of patients with PADH and 11.1% 
(4/36) of patients treated with AS. No IgG antibodies 
were found in plasma, and a cold agglutinin with limited 
thermal range was detected in one of these four patients. 
Three of the four patients with positive DAT were admit-
ted to hospital and treated with high doses of corticos-
teroids, and two of them also required blood transfusion. 
All patients successfully recovered from the haemolysis 
and no relapses occurred. Due to the mildness of the 
anaemia, the remaining patient did not require any treat-
ment. Interestingly, the four patients with positive DAT 
had initially presented with higher parasitaemia than the 
remaining six PADH patients (26.8%, IQR 16.9–36.8 vs. 
5.65%, IQR 4.5–8.0; p = 0.019).
Case descriptions
Cases with Coombs positive haemolytic anaemia after 
AS are described below.
Patient 1
A 55-year-old European traveler presented to the hospi-
tal with a 2-day course of fever after travelling throughout 
Zambia, Malawi, Mozambique and South Africa without 
taking anti-malarial prophylaxis. A blood smear detected 
P. falciparum (parasitaemia 14.8%). The patient was diag-
nosed with severe malaria based on hyperparasitae-
mia and treatment with intravenous AS (2.4  mg/kg) was 
started. However, in the blood smear performed 8 h after 
AS initiation parasitaemia increased to 28.6%. In spite of 
not fulfilling the WHO criteria of AS resistance, treatment 
was changed to intravenous quinine (10 mg/kg/8 h after a 
loading dose of 20 mg/kg) and doxycycline (100 mg/12 h), 
under the clinical suspicion of decreased susceptibility of 
P. falciparum to AS. Blood smear performed 72  h after 
starting this treatment was negative. Quinine was inter-
rupted after 5 doses due to ototoxicity and treatment was 
completed with atovaquone/proguanil for 3 more days.
Eight days after being discharged (and 14  days after 
the first dose of AS) the patient was admitted again for 
a 4-day course of fever, jaundice and dark urine. Two 
consecutive blood smears and a Plasmodium molecu-
lar screening by polymerase chain reaction (PCR) were 
negative. Laboratory tests showed haemolytic anaemia 
with hyperbilirubinaemia, elevation of LDH and unde-
tectable haptoglobin. Haemoglobin levels decreased to 
5.1 g/dL and DAT was positive only for the C3 fraction. 
Other causes of haemolytic anaemia were ruled out: no 
schistocytes were observed on the blood extension, glu-
cose-6-phosphate dehydrogenase (G6PDH) deficiency 
and presence of antinuclear antibodies were discarded, as 
were other infectious aetiologies, such as common viral 
and bacterial infections. Treatment with corticosteroids 
with a loading dose of 250 mg of methylprednisolone and 
1 mg/kg/day of prednisone was started. Transfusion of 4 
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erythrocyte concentrates was also required. The patient 
presented good clinical evolution allowing the discon-
tinuation of corticosteroids after 2  months. Finally, the 
initial suspicion of AS resistance could not be proven by 
mutations on kelch13-propeller domain (k13).
Patient 2
A 55-year-old splenectomized European traveller was 
admitted to the intensive care unit because of severe P. 
falciparum malaria 11  days after returning from Sierra 
Leone. He did not properly take the anti-malarial chemo-
prophylaxis with atovaquone/proguanil as prescribed. 
The patient was diagnosed with severe malaria due to 
hyperparasitaemia (4.7%), acute kidney injury and hyper-
lactacidaemia, that prompted a rapid initiation of intra-
venous AS (2.4 mg/kg). Although clinical and analytical 
improvement were observed, malaria blood smears con-
ducted at 12 and 24 h after AS initiation showed a steady 
increase in parasitaemia up to 8.7%. Under the suspicion 
of AS resistance, treatment was changed to intravenous 
quinine (10  mg/kg/8  h) and doxycycline (100  mg/12  h) 
after the 4th dose of AS. Ten days after admission, the 
patient was discharged asymptomatic and in good clini-
cal condition. Sequencing of k13 showed no molecular 
markers associated to artemisinin resistance. A care-
ful re-evaluation of malaria smears showed pyknotic 
non-viable forms due to the patient’s inability to remove 
erythrocytes from the bloodstream by “pitting”. A blood 
smear on day 28 was finally negative. During follow-up, 
microcytic anaemia (haemoglobin nadir of 9.8  g/dL at 
day 20) with hyperbilirubinaemia, increased LDH and 
undetectable haptoglobin was observed. DAT was posi-
tive for complement and cold agglutinin was detected 
in plasma. Given the mildness of the anaemia and the 
absence of symptoms, no treatment was required. A 
complete recovery was confirmed by laboratory tests 
after 2 weeks.
Patient 3
Eight days after returning from Namibia, Botswana, Zim-
babwe, Malawi and Mozambique, a 40-year-old Euro-
pean traveller was admitted to the hospital for a 6-day 
course of fever and chills. He did not take anti-malarial 
prophylaxis. Diagnosis of severe Plasmodium falciparum 
malaria based on hyperparasitaemia (45%), acute kidney 
injury and respiratory distress was made. The patient was 
admitted to the intensive care unit under mechanical 
ventilation, renal replacement therapy and 2.4  mg/kg of 
intravenous AS. After 5 doses a blood smear was nega-
tive. Anti-malarial treatment was completed with intrave-
nous quinine and doxycycline for 5 more days due to oral 
intolerance. Despite the good parasitological response, 
renal disfunction progressed requiring renal replacement 
therapy. Thirteen days after AS initiation anaemia with 
haemolytic pattern was detected, with a nadir haemo-
globin level of 6.7  g/dL at day 17. Glucose-6-phosphate 
dehydrogenase deficiency, schistocytes and other causes 
of haemolytic anaemia were ruled out and DAT resulted 
positive for the C3 fraction. The patient received a blood 
transfusion without anaemia improvement. Due to the 
kidney injury a renal biopsy was performed and reported 
as compatible with interstitial nephritis. Three pulses 
of 250  mg methylprednisolone were then prescribed. 
Regarding the anaemia, although a blood transfusion 
had previously been administered, haemoglobin concen-
tration did not raise until corticosteroid treatment was 
initiated. The patient was finally discharged with a daily 
dose of 40 mg of prednisone and complete recovery was 
observed within the following month.
Patient 4
A 49-year-old European man who frequently travelled 
to West Africa for business was admitted to the inten-
sive care unit of the hospital after travelling to Liberia. 
He had not taken anti-malarial prophylaxis. The patient 
was diagnosed with severe P. falciparum malaria based 
on hyperparasitaemia (25%), acute kidney injury, respira-
tory distress and hyperbilirubinaemia. Following the hos-
pital protocols, after the first intravenous AS dose, red 
blood cell exchange was performed. Subsequently, four 
more doses of intravenous AS were administered. The 
patient had an excellent clinical, analytical and parasito-
logical evolution with a parasite clearance time of 70 h. 
Anti-malarial treatment was then completed with a 3-day 
course of dihydroartemisinin/piperaquine. Seven days 
after being discharged the patient had to be readmit-
ted due to haemolytic anaemia, with a nadir haemoglo-
bin level of 7.7 g/dL at day 16. DAT was positive for the 
C3d fraction of the complement and daily treatment with 
100 mg methylprednisolone was started. Finally, a blood 
transfusion was performed after the DAT was negative. 
The patient was finally discharged with haemoglobin lev-
els of 8.4 g/dL. Two weeks after, the patient remained in 
good clinical condition and the haemoglobin levels raised 
up to 9.6 g/dL.
Discussion
Post-artesunate delayed haemolysis is increasingly being 
reported after anti-malarial treatment with artemisinins. 
In this series of 36 patients treated with parenteral AS, 
PADH occurred in over a fourth (27.8%) of patients 
treated with AS. Of these, DAT was positive in 4 of the 6 
patients in whom the test was performed, which amounts 
to at least the 40% of patients with PADH. The true inci-
dence of positive Coombs haemolysis after AS treatment 
is unknown. Since mechanical destruction of red blood 
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Table 1 Summary of features of patients with immune-mediated post-artesunate delayed haemolysis (PADH)


















M 55 Non‑immune P.f. 28.6 Hyperparasitae‑
mia
2 4 14 5.1 13
M 55 Non‑immune P.f. 8.7 Hyperparasitae‑
mia, AKI, hyper‑
lactaemia
4 20c 20 9.6 26
M 40 Non‑immune P.f. 45 Hyperparasitae‑
mia, AKI, respira‑
tory distress
5 3 9 6.1 12





5 3 13 7.7 16
F 17 Semi‑immune P.f. 0.8 Shock, hyperlac‑
taemia
3 3 14 4.6 16
M 43 Non‑immune P.f. 30 Hyperparasitae‑
mia, prostration 
(psychomotor 
slow down), AKI, 
acidosis and 
hyperlactaemia
– – 8 5.3 18
M 78 Non‑immune P.f. 27 Hyperparasitae‑
mia, AKI
– 1.5 15 6.4 15




2 4 – 6.9 20
F 44 – P.f. 37 Hyperparasitae‑
mia
3 4 – 6.1 15




1 10 – 6.9 13






4 7 – 5.7 14





5 – 10 5.6 –







– 5 7 4.1 11
– – P.f. – – – – – – –
Gender, age Coombs Treatment Survival Ref. Country Year Frequencyb
M 55 C3d+ Corticosteroids and blood transfusion Yes Our cases Spain 2018 40% (4/10)
M 55 C3d+ and cryoagglutinins None Yes Our cases Spain 2018 40% (4/10)
M 40 C3d+ Corticosteroids and blood transfusion Yes Our cases Spain 2018 40% (4/10)
M 49 C3d+ Corticosteroids and blood transfusion Yes Our cases Spain 2018 40% (4/10)
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cells (RBC) has been assumed as the main mechanism 
of haemolysis after AS, DAT has not been systematically 
performed and it has only been occasionally reported 
in most PADH case series. As a consequence, positive 
Coombs haemolytic anaemia after AS raises as a prob-
able misdiagnosed entity.
Interestingly, in these 4 cases, DAT was positive only 
for complement—without IgG—as it was in two previ-
ously reported cases with specific information about the 
test [5, 10–16] (see Table  1). This pattern of DAT posi-
tivity is typical of the drug-dependent immune-haemo-
lytic anaemia (IHA) of the immune-complex type [19], 
although it can also be seen in IHAs mediated by cold-
agglutinins, biphasic haemolysins, and systemic immune-
mediated disorders with strong complement activation, 
such some infectious events. There is little evidence 
about these immune delayed phenomena, but recent data 
suggest that post-malaria neurologic syndromes could 
also have an immunological mechanism [20]. Confirma-
tion of drug-induced mechanism requires the demon-
stration of drug-dependent antibodies in the patient’s 
serum [10], which is a difficult task because of the intri-
cacies of reproducing in vitro the in vivo conditions and 
because antibodies may recognize a metabolite instead of 
the original drug [20]. Positive DAT—with specific sub-
classes of IgG directed to parasite antigens—has been 
previously described in children from endemic coun-
tries with malaria and anaemia during the acute phase 
of the malaria infection [21, 22]. Despite that, the differ-
ent pattern of DAT positivity might suggest a different 
pathophysiological mechanism of positive DAT delayed 
haemolysis, probably secondary to the use of AS [19].
Splenic “pitting” of parasites from infected erythro-
cytes, that has been related with initial parasitaemia, 
histidine-rich protein 2 (HRP2) and concentration of 
once-infected erythrocytes after treatment, has been 
proposed as the main mechanism for PADH [5]. These 
once-infected, “pitted” RBC become rigid spherocytes, 
and are removed from the circulation in subsequent pas-
sages through the spleen [5]. “Pitting” plays an important 
role in removing parasites from infected erythrocytes 
[23] and, in fact, PADH is more frequent in patients pre-
senting with high parasitaemia or with a large number 
of residual spherocytes after effective treatment with AS 
[5]. However, given the mechanism of action of AS, “pit-
ting” cannot explain all cases of haemolysis, as evidenced 
in the in splenectomized patients. Moreover, it is worth 
noticing that C3-coated RBC also become spherocytes 
before being removed from the circulation and might, 
therefore, be accounted for as pitted erythrocytes.
Furthermore, in all but one of the 4 patients with a 
positive DAT, PADH was severe enough as to require 
hospital admission and RBC transfusion. Treatment with 
corticosteroids in these 3 patients was followed by a rapid 
resolution of the haemolytic crisis, an outcome already 
observed in 6 of the 8 previously reported patients with 
PADH and positive DAT (see Table  1). However, it is 
important to be cautious before attributing therapeutic 
efficacy to corticosteroids in these cases. Indeed, both in 
PADH and drug-dependent IHA, the haemolytic process 
is self-limited once all the pitted erythrocytes have been 
removed and also when the drug has been cleared from 
the patient’s plasma.
This retrospective study has some limitations. On the 
one hand, DAT was only performed in some cases after 
AKI acute kidney injury, F female, Hb haemoglobin, M male, PCT parasite clearance time, P.f. Plasmodium falciparum, Ref Reference
a Counted from artesunate initiation
b Frequency of immune-mediated PADH cases among the overall of PADH patients reported in each article
c Although non-viable pyknotic forms of Plasmodium were seen until day 20 after artesunate initiation, trophozoites could only be detected until day 6
Table 1 (continued)
Gender, age Coombs Treatment Survival Ref. Country Year Frequencyb
F 17 IgG+ and C3d+ (positive 
drug‑dependent antibod‑
ies test)
Corticosteroids Yes [10] France 2014 100% (1/1)
M 43 C3d+ Corticosteroids Yes [11] France 2018 100% (1/1)
M 78 Direct Coombs Corticosteroids and blood transfusion Yes [12] United Kingdom 2012 100% (1/1)
M 53 C3d+ None Yes [13] Belgium/Netherlands 2012 50% (3/6)
F 44 IgG+ and C3d+ Corticosteroids and blood transfusion Yes [13] Belgium/Netherlands 2012 50% (3/6)
F 59 IgG+ and IgM+ Corticosteroids and blood transfusion Yes [13] Belgium/Netherlands 2012 50% (3/6)
M 54 IgG+ (anti‑E specificity) Blood transfusion Yes [14] Germany 2012 33% (1/3)
F 44 No data Blood transfusion Yes [15] Spain 2017 25% (1/4)
F 50 IgG+ Corticosteroids and blood transfusion Yes [16] India 2018 100% (1/1)
– IgM+ – – [5] France 2014 8% (1/13)
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the haemolysis appeared (6 of the 10 cases with PADH). 
As a consequence, DAT positivity due to malaria itself, 
although less probable, cannot be completely ruled out. 
The inclusion of a control group could have contributed 
to assess this problem. On the other hand, other causes of 
haemolysis such as drug-induced haemolysis due to dif-
ferent drugs such as beta-lactams, which were prescribed 
in the four patients, or quinine, which was given to 3 of 
the 4 patients, cannot be excluded. This is a hypothesis-
generating study highlighting the importance of perform-
ing DAT when haemolysis after AS is detected.
Conclusions
These cases, together with those previously published, 
highlight the possible contribution of autoimmune mech-
anisms to haemolysis due to artemisinins in selected 
cases and reopen the debate about the possible benefit of 
corticosteroids [10–13, 16]. Coombs positive haemolytic 
anaemia after AS is possibly underreported, due to the 
assumption of “pitting” as the mechanism of haemolysis. 
The presented results suggest that mechanical destruc-
tion of once-infected “pitted” erythrocytes is no longer 
the exclusive mechanism to explain haemolysis after AS. 
Consequently, DAT should be performed in all cases of 
suspected haemolysis during the follow-up of patients 
treated with AS in order to rule out immune-mediated 
haemolytic anaemia [24]. Further studies are necessary 
to clarify the role of immune-mediated mechanisms in 
PADH with positive DAT and the possible therapeutic 
efficacy of corticosteroids.
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